CEO: Amber Salzman

Advent Contact: Shahzad Malik

Clinical development of cardio-renal drugs

Cardiokine was a specialty pharmaceutical company founded around the licensing of Lixivaptan from Wyeth Pharmaceuticals in 2004. Lixivaptan is a sodium sparing diuretic that had completed multiple Phase I and Phase II trials.

Advent invested in the Series B in 2006. The Company was sold to Cornerstone Therapeutics in 2012.